NASDAQ:PAND

Pandion Therapeutics Stock Forecast, Price & News

$10.87

+0.13 (+1.21 %)

(As of 10/29/2020 02:52 PM ET)

Add

Compare

Today's Range

$10.44

Now: $10.87▼

$10.95

50-Day Range

$10.73

MA: $12.70▼

$18.35

52-Week Range

$10.28

Now: $10.87▼

$27.75

Volume2,037 shs

Average Volume148,594 shs

Market Capitalization$320.88 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Pandion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.50, Pandion Therapeutics has a forecasted upside of 143.8% from its current price of $10.87.
Amount of Analyst Coverage
Pandion Therapeutics has only been the subject of 4 research reports in the past 90 days.

4.3 Community Rank

Outperform Votes
Pandion Therapeutics has received 6 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Pandion Therapeutics has received 1 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Pandion Therapeutics has received 85.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pandion Therapeutics and other stocks. Vote “Outperform” if you believe PAND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAND will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Pandion Therapeutics does not currently pay a dividend.
Dividend Growth
Pandion Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pandion Therapeutics insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Pandion Therapeutics are expected to grow in the coming year, from ($1.85) to ($1.74) per share.

Overall Beat the Market Rank^™

1.69 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PAND

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.pandiontx.com

Phone617-393-5925

Employees43

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares29,520,000

Market Cap$320.88 million

Next Earnings Date11/30/2020 (Estimated)

OptionableNot Optionable

$10.87

+0.13 (+1.21 %)

(As of 10/29/2020 02:52 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PAND News and Ratings via Email

Sign-up to receive the latest news and ratings for PAND and its competitors with MarketBeat's FREE daily newsletter.

Pandion Therapeutics (NASDAQ:PAND) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pandion Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pandion Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pandion Therapeutics.

When is Pandion Therapeutics' next earnings date?

Pandion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 30th 2020.
View our earnings forecast for Pandion Therapeutics.

How were Pandion Therapeutics' earnings last quarter?

Pandion Therapeutics, Inc. (NASDAQ:PAND) announced its quarterly earnings data on Monday, August, 31st. The company reported ($10.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $9.54. The company had revenue of $1.96 million for the quarter, compared to the consensus estimate of $1 million.
View Pandion Therapeutics' earnings history.

What price target have analysts set for PAND?

4 analysts have issued 1 year price objectives for Pandion Therapeutics' shares. Their forecasts range from $24.00 to $29.00. On average, they anticipate Pandion Therapeutics' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price.
View analysts' price targets for Pandion Therapeutics.

Who are some of Pandion Therapeutics' key competitors?

Some companies that are related to Pandion Therapeutics include Epizyme (EPZM), Arcturus Therapeutics (ARCT), Theravance Biopharma (TBPH), Mersana Therapeutics (MRSN), NGM Biopharmaceuticals (NGM), Trillium Therapeutics (TRIL), Endo International (ENDP), Kiniksa Pharmaceuticals (KNSA), Karyopharm Therapeutics (KPTI), Zogenix (ZGNX), Generation Bio (GBIO), Applied Molecular Transport (AMTI), Constellation Pharmaceuticals (CNST), MacroGenics (MGNX) and Cytokinetics (CYTK).
View all competitors.

What other stocks do shareholders of Pandion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pandion Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Moderna (MRNA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Curaleaf (CURLF), Dynavax Technologies (DVAX), Evofem Biosciences (EVFM), NGM Biopharmaceuticals (NGM) and Opko Health (OPK).

Who are Pandion Therapeutics' key executives?

Pandion Therapeutics' management team includes the following people:

Dr. Rahul Kakkar, CEO & Director (Age 45, Pay $483.67k)
Dr. Joanne L. Viney Ph.D., Pres & Chief Scientific Officer (Age 54, Pay $543.01k)
Mr. Vikas Goyal, Sr. VP of Bus. Devel. (Age 41, Pay $146.25k)
Mr. Gregg D. Beloff, Interim Chief Financial Officer (Age 52)
Mr. Edward D. Freedman J.D., Esq., Chief Operating Officer (Age 51)

When did Pandion Therapeutics IPO?

(PAND) raised $94 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 5,500,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

What is Pandion Therapeutics' stock symbol?

Pandion Therapeutics trades on the NASDAQ under the ticker symbol "PAND."

When does the company's lock-up period expire?

Pandion Therapeutics' lock-up period expires on Wednesday, January 13th. Pandion Therapeutics had issued 7,500,000 shares in its initial public offering on July 17th. The total size of the offering was $135,000,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Pandion Therapeutics?

Shares of PAND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pandion Therapeutics' stock price today?

One share of PAND stock can currently be purchased for approximately $10.87.

How big of a company is Pandion Therapeutics?

Pandion Therapeutics has a market capitalization of $320.88 million. Pandion Therapeutics employs 43 workers across the globe.

What is Pandion Therapeutics' official website?

The official website for Pandion Therapeutics is www.pandiontx.com.

How can I contact Pandion Therapeutics?

Pandion Therapeutics' mailing address is 134 COOLIDGE AVENUE 2ND FLOOR, WATERTOWN MA, 02472. The company can be reached via phone at 617-393-5925 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings